Asclepix Therapeutics, Inc. AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference To Provide Update on AXT107 Duration of…
Read More
Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for…